| First Author | Christadoss P | Year | 1988 |
| Journal | J Immunol | Volume | 140 |
| Issue | 8 | Pages | 2589-92 |
| PubMed ID | 3356901 | Mgi Jnum | J:27627 |
| Mgi Id | MGI:75116 | Doi | 10.4049/jimmunol.140.8.2589 |
| Citation | Christadoss P (1988) C5 gene influences the development of murine myasthenia gravis. J Immunol 140(8):2589-92 |
| abstractText | The influence of the C5 gene and C5 deficiency on murine experimental autoimmune myasthenia gravis (EAMG) susceptibility was evaluated. Two co-isogenic strains, B10.D2/nSn (C5 sufficient) and B10.D2/oSn (C5 deficient), which are genetically identical except for the C5 gene locus, were immunized with acetylcholine receptors (AChR) in CFA to induce myasthenia gravis. Both strains had equivalent concentration of serum autoantibodies to muscle AChR and antibodies bound to muscle AChR. C5-sufficient B10.D2/nSn, but not C5-deficient B10.D2/oSn, demonstrated increased incidence of clinical disease and death and lost significant amounts of muscle AChR. Therefore, C5 deficiency in B10.D2/oSn prevented EAMG. C5 gene, which codes for C component C5, may influence EAMG pathogenesis through activation of the terminal lytic C sequence (C5 to C9) required for muscle AChR destruction, which is the primary pathology. |
